Levetiracetam Effective as Episodic Migraine Prophylactic
Insufficient evidence is available to determine the efficacy of levetiracetam as a chronic migraine prophylactic.
The characteristics of white matter hyperintensities were assessed to provide information on the underlying mechanisms of these lesions in individuals with reversible cerebral vasoconstriction syndrome.
Researchers sought to assess the prevalence of concomitant prescribing of opioid analgesics with a triptan or a serotogeneric antidepressant in individuals with migraine.
Teva has decided to discontinue part of the ENFORCE Phase 3 clinical development program for fremanezumab.